TEL AVIV, Israel, April 29, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that management will present a company overview at the following conferences in May:
- Deutsche Bank 40th Annual Health Care Conference in Boston, MA on Wednesday, May 6, 2015, at 2:50 p.m. ET. A live webcast will be available by visiting the investor relations section of VBL's website at www.vblrx.com. An archived replay of the webcast will be available on the Company's website for 90 days after the conference.
- Oppenheimer 16th Annual Israeli Conference, in Tel-Aviv, Israel on Sunday, May 10, 2015, at 1:10 p.m. IST (6:10 am ET).
- IATI Biomed 2015 Conference in Tel Aviv, Israel on Wednesday, May 13, 2015, at 2:20 p.m. IST (7:20 a.m. ET).
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. VBL has also developed a proprietary platform of small molecules, Lecinoxoids, for the treatment of chronic immune-related indications. The Company's lead oncology product candidate, VB-111, is a gene-based biologic that is initially being developed for recurrent glioblastoma, or rGBM, an aggressive form of brain cancer. VB-111 has received orphan drug designation in both the United States and Europe and was granted Fast Track designation by the FDA for prolongation of survival in patients with glioblastoma that has recurred following treatment with standard chemotherapy and radiation. VBL Therapeutics expects to begin the pivotal Phase 3 trial for VB-111 in rGBM in mid-2015, under a special protocol assessment agreement granted by the FDA.
CONTACT: Hannah Deresiewicz Stern Investor Relations, Inc. 212-362-1200, firstname.lastname@example.orgSource: VBL Therapeutics